ADDITIONAL SOUTHERN CALIFORNIA BREAST HEALTH CENTERS ADD DIGNICAP® TO THEIR PATIENT TREATMENT OFFERINGS

Lund, Sweden —October 4, 2016— Dignitana AB, a world leader in medical scalp-cooling technology, announced today that the DigniCap ® scalp cooling system, which was cleared in 2015 by the FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, will be available at all five Breastlink centers in the U.S.  The DigniCap ® system is the first and only scalp cooling device to complete rigorous FDA clinical trials in America, where seven out of ten patients with early-stage breast cancer kept at least 50% of their hair.

On the heels of the FDA Clearance, medical centers across the country have begun offering the DigniCap® scalp cooling system as part of the comprehensive cancer care treatment services they provide. Through funding from a recent Private Placement and Rights Offering, Dignitana’s US presence is rapidly expanding as demand for the medical device accelerates. Breastlink, a comprehensive breast health center with five locations in Southern California will be offering DigniCap® scalp cooling systems as part of their breast cancer treatment and care regimens. Breastlink offers women a comprehensive breast cancer risk assessment program to help empower them about their health care options.

DigniCap® scalp cooling system will be offered in all of the Breastlink Health Centers. Locations are as follows:

“We are pleased with the consistent strong growth we are experiencing in the U.S. since FDA clearance nine months ago,” said Jan Richardsson, Chief Executive Officer of Dignitana. “The DigniCap system is being included as an integral part of the treatments offered by national leaders in comprehensive breast health services in the U.S. Up to date, forty-seven DigniCap scalp-cooling systems have been ordered for installation by US customers.”

The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

Media Contact:

Jan Richardsson
CEO, Dignitana AB (publ)

Ph   +46 (0)46 16 30 92
E  jan.richardsson@dignitana.com

About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Adviser. For more information visit www.dignitana.com

About the scalp cooling system DigniCap®
Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® is developed to provide continuous cooling with high efficacy, safety and acceptable patient comfort.

Tags:

About Us

Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Advisor. For more information visit www.dignitana.com Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® is developed to provide continuous cooling with high efficacy, safety and acceptable patient comfort.

Subscribe

Documents & Links

Quotes

We are pleased with the consistent strong growth we are experiencing in the U.S. since FDA clearance nine months ago. The DigniCap system is being included as an integral part of the treatments offered by national leaders in comprehensive breast health services in the U.S. Up to date, forty-seven DigniCap scalp-cooling systems have been ordered for installation by US customers.
Jan Richardsson, Chief Executive Officer of Dignitana